Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β-cells of the pancreas along with insulin, after a meal. Like insulin, amylin is completely absent in individuals with Type I diabetes.
CAT No:10-101-28
CAS No:151126-32-8
Synonyms/Alias:AC 0137; AC 137; Symlin; Tripro-Amylin; riproamylin; Pramlintide; LS-181996; LS181996; Amylin
Quick InquiryPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C171H267N51O53S2 |
M.W/Mr. | 3949.4 |
Sequence | Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2(Disulfide bridge cys2 and cys7) |
Labeling Target | Amylin receptor |
Application | Pramlintide (Symlin) has been approved by the FDA as a new injectable drug for diabetes (both type 1 and 2). |
Activity | Agonist |
Biological Activity | Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer. |
Areas of Interest | Metabolic Disease |
Functions | Receptor activity |
Target | Calcitonin receptor |
Source# | Synthetic |
Solubility | −20°C |
Organism | Human |
BoilingPoint | N/A |
Melting Point | N/A |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.